Cargando…
Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
RATIONALE: Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed. OBJECTIVE: The aim of this study is to characterize the preclinical profile of ITI-214, a potent inhibitor of phosphodiesterase 1 (PDE1). METHODS: ITI-214 was assayed for inhibi...
Autores principales: | Snyder, Gretchen L., Prickaerts, Jos, Wadenberg, Marie-Louise, Zhang, Lei, Zheng, Hailin, Yao, Wei, Akkerman, Sven, Zhu, Hongwen, Hendrick, Joseph P., Vanover, Kimberly E., Davis, Robert, Li, Peng, Mates, Sharon, Wennogle, Lawrence P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980415/ https://www.ncbi.nlm.nih.gov/pubmed/27342643 http://dx.doi.org/10.1007/s00213-016-4346-2 |
Ejemplares similares
-
M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY
por: Satlin, Andrew, et al.
Publicado: (2020) -
S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY
por: Vanover, Kimberly, et al.
Publicado: (2018) -
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
por: Snyder, Gretchen L., et al.
Publicado: (2014) -
F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018) -
Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
por: Vanover, Kimberly E., et al.
Publicado: (2018)